These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 22615450)

  • 1. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
    Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
    Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.
    Castriconi R; Dondero A; Augugliaro R; Cantoni C; Carnemolla B; Sementa AR; Negri F; Conte R; Corrias MV; Moretta L; Moretta A; Bottino C
    Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12640-5. PubMed ID: 15314238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
    Brodzik R; Glogowska M; Bandurska K; Okulicz M; Deka D; Ko K; van der Linden J; Leusen JH; Pogrebnyak N; Golovkin M; Steplewski Z; Koprowski H
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8804-9. PubMed ID: 16720700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96.
    Fauci JM; Sabbatino F; Wang Y; Londoño-Joshi AI; Straughn JM; Landen CN; Ferrone S; Buchsbaum DJ
    Gynecol Oncol; 2014 Jan; 132(1):203-10. PubMed ID: 24216048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
    Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.
    Noguchi T; Kato T; Wang L; Maeda Y; Ikeda H; Sato E; Knuth A; Gnjatic S; Ritter G; Sakaguchi S; Old LJ; Shiku H; Nishikawa H
    Cancer Res; 2012 Apr; 72(7):1672-82. PubMed ID: 22318866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preparation of anti-B7-H4 monoclonal antibody to investigate B7-H4 expression in pancreatic cancer].
    Hong B; Qian Y; Yao HP
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 42(5):511-6. PubMed ID: 24167131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
    Kinouchi T; Bander NH; Kotake T
    J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.